参考:Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004Green Light for Phase 2 Trial of AST-004 in Acute Ischemic Stroke Patients | BioSpace 发布于 2024-03-13 10:40・江苏 FDA 中风偏瘫 ...
处于临床阶段的药物研发公司Astrocyte Pharmaceuticals Inc.宣布B轮过桥融资超额认购超过600万美元，本轮融资由Dreavent Capital领投，阿尔茨海默氏症药物研发基金会（Alzheimer's Drug Discovery Foundation）和其他投资者跟投。这笔资金将加速 AST-004 的临床开发，AST-004 是一种极具潜力的候选疗法，旨在治疗包括中风和创...
处于临床阶段的药物研发公司Astrocyte Pharmaceuticals Inc.宣布B轮过桥融资超额认购超过600万美元,本轮融资由DreaventCapital领投,阿尔茨海默氏症药物研发基金会(Alzheimer's Drug Discovery Foundation)和其他投资者跟投。这笔资金将加速 AST-004 的临床开发,AST-004 是一种极具潜力的候选疗法,旨在治疗包括中风和创伤性脑...
drug interactionsstroketenecteplasethrombolytic therapytissue-type plasminogen activatorBACKGROUND: AST-004, a small molecule agonist of the adenosine A1 and A3 receptors, is a potential cerebroprotectant for patients with acute stroke and is currently in clinical trials. Drug-drug interactions are ...
In part 2, all 12 subjects received a 100 mg IV infusion of the study drug followed by a single CSF collection per subject via lumbar puncture at 20, 40, or 60 minutes after infusion.#A total of 42 subjects received AST-004, with no severe or serious adverse events observed. Twelve ...